Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.73 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.73 |
| ▸ | POLB | P06746 | 2/20 | 0.59 |
| ▸ | TSHR | P16473 | 3/20 | 0.58 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.56 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.50 |
| ▸ | THRB | P10828 | 1/20 | 0.49 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6534174 | 1.00 | KDM4E (0.73) | KDM4ESMN1; SMN2POLBTSHRNPSR1 | |
| SCHEMBL7670891 | 0.87 | KDM4E (0.69) | KDM4ESMN1; SMN2POLBTSHRNPSR1 | |
| SCHEMBL7837671 | 0.87 | KDM4E (0.69) | KDM4ESMN1; SMN2POLBTSHRNPSR1 | |
| SCHEMBL7670889 | 0.85 | KDM4E (0.71) | KDM4ESMN1; SMN2POLBTSHRNPSR1 | |
| SCHEMBL7837668 | 0.85 | KDM4E (0.71) | KDM4ESMN1; SMN2POLBTSHRNPSR1 | |
| SCHEMBL7336982 | 0.83 | KDM4E (0.53) | KDM4ESMN1; SMN2POLBNPSR1ALDH1A1 | |
| SCHEMBL7405457 | 0.83 | KDM4E (0.53) | KDM4ESMN1; SMN2POLBNPSR1ALDH1A1 | |
| SCHEMBL27738022 | 0.79 | KDM4E (0.48) | KDM4ESMN1; SMN2POLBTSHRNPSR1 | |
| SCHEMBL5736424 | 0.77 | KDM4E (0.66) | KDM4ESMN1; SMN2POLBTSHRNPSR1 | |
| SCHEMBL18051877 | 0.77 | KDM4E (0.61) | KDM4ESMN1; SMN2POLBTSHRNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060160856-A1 | Diarylurea derivatives and their use as chloride channel blockers | NEUROSEARCH A/S (DK) | 2006-07-20 | — | — | US | claimed |
| JP-2005538152-A | — | — | 2005-12-15 | — | — | JP | claimed |
| EP-1537075-A2 | DIARYLUREA DERIVATIVES AND THEIR USE AS CHLORIDE CHANNEL BLOCKERS | NEUROSEARCH A/S (DK) | 2005-06-08 | — | — | EP | claimed |
| WO-2004022529-A2 | DIARYLUREA DERIVATIVES AND THEIR USE AS CHLORIDE CHANNEL BLOCKERS | NEUROSEARCH A/S (DK) | 2004-03-18 | — | — | WO | claimed |
| US-20060160856-A1 | Diarylurea derivatives and their use as chloride channel blockers | NEUROSEARCH A/S (DK) | 2006-07-20 | — | — | US | disclosed |
| EP-1537075-A2 | DIARYLUREA DERIVATIVES AND THEIR USE AS CHLORIDE CHANNEL BLOCKERS | NEUROSEARCH A/S (DK) | 2005-06-08 | — | — | EP | disclosed |
| WO-2004022529-A2 | DIARYLUREA DERIVATIVES AND THEIR USE AS CHLORIDE CHANNEL BLOCKERS | NEUROSEARCH A/S (DK) | 2004-03-18 | — | — | WO | disclosed |
| US-20020007075-A1 | Ureas of N-heterocyclic carboxylic acids and carboxylic acid isosteres | GLIAMED, INC. | 2002-01-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020007075-A1 | Ureas of N-heterocyclic carboxylic acids and carboxylic acid isosteres | OTC, CPS1, ABAT | KDM4E 2622/4885SMN1; SMN2 573/4885POLB 2320/4885 |
| US-20060160856-A1 | Diarylurea derivatives and their use as chloride channel blockers | KIT, ORAI1, CACNA1C | KDM4E 1042/4885SMN1; SMN2 2548/4885POLB 3428/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.